Dec 30: The Subject Expert Committee (SEC) in the Central Drugs Standard Control Organisation (CDSCO) met today in the afternoon to consider the Emergency Use Authorisation (EUA) request of Pfizer, Serum Institute of India (SII) and Bharat Biotech Pvt. Ltd.
Further time was requested on behalf of Pfizer. The additional data and information presented by SII and Bharat Biotech Pvt. Ltd. was perused and analysed by the SEC.
The analysis of the additional data and information is going on. SEC will convene again on 1st January 2021 (Friday).
Disclaimer: We donot claim that the images used as part of the news published are always owned by us. From time to time, we use images sourced as part of news or any related images or representations. Kindly take a look at our image usage policy on how we select the image that are used as part of the news.
